Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) Assets Average (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Assets Average for 11 consecutive years, with $18.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets Average rose 61.62% to $18.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $18.3 million, a 61.62% increase, with the full-year FY2024 number at $19.6 million, down 24.05% from a year prior.
  • Assets Average was $18.3 million for Q3 2025 at Marker Therapeutics, up from $15.9 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $84.4 million in Q2 2021 to a low of $11.3 million in Q3 2024.
  • A 5-year average of $37.0 million and a median of $24.9 million in 2023 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: soared 84.7% in 2021, then crashed 55.65% in 2023.
  • Marker Therapeutics' Assets Average stood at $70.0 million in 2021, then tumbled by 46.07% to $37.8 million in 2022, then tumbled by 51.53% to $18.3 million in 2023, then decreased by 10.05% to $16.5 million in 2024, then increased by 10.84% to $18.3 million in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Assets Average are $18.3 million (Q3 2025), $15.9 million (Q2 2025), and $19.5 million (Q1 2025).